Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient
NCT03195452Phase 2Completed
- Sponsor
- CHU de Nantes
- Start
- Nov 2017
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of raltegravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by CHU de Nantes. Primary endpoint: Plasma HIV-1 RNA Viral Load at 48 weeks. Started Nov 2017; status: completed.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03195452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03195452.